Trial Profile
XELOX for 4 Months Versus 6 Months as Adjuvant Chemotherapy in Gastric Cancer After D2 Resection (LOMAC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- Acronyms LOMAC
- 10 Mar 2024 Planned End Date changed from 1 Dec 2025 to 1 Aug 2026.
- 10 Mar 2024 Planned primary completion date changed from 1 Dec 2022 to 1 Aug 2026.
- 10 Mar 2024 Status changed from recruiting to active, no longer recruiting.